ABSTRACT Background Respiratory syncytial virus (RSV) is increasingly recognized as a trigger for adverse outcomes in older adults with heart failure (HF). Following FDA approval of RSV vaccines for adults ≥ 60 years in 2023, real‐world evidence in HF populations remains limited. Methods We conducted a multicenter retr...
Allahdad Khan, M. R. Shabbir, Jamil Nasrallah et al.· Clinical Cardiology· 0 citations
BACKGROUND
The C-MIC II trial demonstrated benefits of 6 months of cardiac microcurrent (C-MIC) therapy in patients with non-ischemic heart failure with reduced ejection fraction (HFrEF). The prospective C-MIC II Follow-Up Study evaluates safety and efficacy outcomes post-device deactivation.
METHODS
Primary safety-r...
J. Rame, D. Kosevic, T. Kovačević-Preradović et al.· European Journal of Heart Fa...· 0 citations
BACKGROUND
Real-world data regarding diuretic strategies and associated outcomes in patients hospitalized for heart failure (HF) in community health systems are limited.
OBJECTIVES
Evaluate associations between initial diuretic therapy, markers of decongestion, and clinical outcomes in patients hospitalized for HF....
A. Varshney, A. Ambrosy, Adam Furst et al.· Journal of Cardiac Failure· 0 citations
Consistent improvements in LVEF, 6MWD and KCCQ-OSS across SGLT2i subgroups suggest that the observed benefits are independent of background pharmacologic intensification.
Marat Fudim, T. Kovačević-Preradović, D. Kosevic et al.· ESC Heart Failure· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
